Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ilaprazole · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Ilaprazole 5 mg QD | EXPERIMENTAL | - |
| Ilaprazole 20 mg QD | EXPERIMENTAL | - |
| Ilaprazole 40 mg QD | EXPERIMENTAL | - |
| Lansoprazole 30 mg QD | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ilaprazole | DRUG | Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks. |
| Lansoprazole | DRUG | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. |
Inclusion Criteria: * Subject must have endoscopically confirmed erosive esophagitis as defined by the Los Angeles (LA) Classification Grading System (A-D). Exclusion Criteria: * Evidence of uncontrolled, clinically significant systemic disease; acquired immunodeficiency syndrome (AIDs); a condit...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tezepelumab |
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | dupilumab |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | PHASE2 | Vonoprazan |
| Eupraxia Pharmaceuticals, Inc. | EPRX | 1 | PHASE1 | EP-104GI |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Dupilumab |
Ilaprazole is being developed for the treatment of esophagitis, specifically erosive esophagitis. It is a small molecule in the gastrointestinal therapeutic area. The clinical program has studied it for healing of erosive esophagitis, a condition where acid damage erodes the lining of the esophagus.
Ilaprazole targets ATP4A and ATP4B, which together form the gastric proton pump. It acts as an inhibitor of this target. By inhibiting the proton pump, ilaprazole reduces gastric acid secretion, which is the mechanism relevant to treating erosive esophagitis.
Ilaprazole is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor associated with the clinical development of this small molecule for gastrointestinal indications.
Ilaprazole is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 program has focused on esophagitis, with one completed trial to date.
Ilaprazole has been studied in one completed clinical trial, NCT00471094. This Phase 2 trial evaluated the safety and efficacy of ilaprazole at 5, 20, and 40 mg once daily compared with lansoprazole 30 mg once daily for healing of erosive esophagitis. It enrolled 831 participants in the United States.
No, ilaprazole and lansoprazole are different drugs. Ilaprazole is a distinct small molecule developed by Takeda, while lansoprazole was used as the active comparator in the Phase 2 trial NCT00471094. Both belong to the proton pump inhibitor class, but they are separate chemical entities.